Tumor cells can enhance the expression of SLC7A11 by deactivating tumor suppressor factors (such as P53, BAP1, and ARF) and activating KRAS expression [65–68], while high expression of GSH and GPX-4 is also confirmed in various tumor cells [69, 70]. Here, CDKN2A is linked to neoplasm.